ST3GAL5 Antibody

What is ST3GAL5 and what cellular functions does it regulate?

ST3GAL5 (ST3 beta-Galactoside alpha-2,3-Sialyltransferase 5) functions as a key enzyme that transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the non-reducing terminal galactose of glycosphingolipids, forming gangliosides. It primarily catalyzes the conversion of lactosylceramide (LacCer) into monosialodihexosylganglioside 3 (GM3), which serves as a precursor for a-, b-, and c-series gangliosides . While GM3 synthesis represents its main function, ST3GAL5 can also sialylate other glycolipid substrates including D-galactosylceramide (GalCer), asialo-GM2 (GA2), and asialo-GM1 (GA1), though with lower efficiency than with LacCer .

ST3GAL5-produced gangliosides regulate multiple cellular processes including:

• Cell proliferation and differentiation

• Apoptosis

• Embryogenesis and development

• Cell adhesion and membrane organization

• Oncogenesis and tumor progression

• Immune cell modulation and inflammatory responses

In the Golgi apparatus, ST3GAL5 catalyzes the first step in ganglioside synthesis, making it a critical regulatory node in glycosphingolipid metabolism and cellular signaling pathways .

What applications are ST3GAL5 antibodies suitable for in research?

ST3GAL5 antibodies have been validated and optimized for multiple experimental applications, with specific considerations for each method:

When designing experiments with ST3GAL5 antibodies, researchers should consider targeting specific amino acid regions (e.g., AA 151-200) depending on research goals. Polyclonal antibodies offer broader epitope recognition but may show batch-to-batch variability, while monoclonal antibodies provide higher specificity for discrete epitopes .

Multiple species reactivity (human, mouse, rat, horse, pig, rabbit, hamster, monkey) has been documented for some antibodies, making them versatile tools for comparative studies .

How should researchers validate ST3GAL5 antibody specificity?

Methodological validation of ST3GAL5 antibody specificity should include:

• Positive and negative control tissues/cells: Use tissues with known expression levels (HEK-293, Jurkat, HeLa cells, human testis, and placenta tissue have been validated as positive controls) .

• Knockout/knockdown validation: Compare staining between wild-type samples and those where ST3GAL5 has been knocked out or knocked down using CRISPR/Cas9 or siRNA methods. Published studies have successfully used this approach to validate antibody specificity .

• Western blot analysis: Confirm the expected molecular weight (45-50 kDa observed) and single band specificity. Multiple bands could indicate non-specific binding or post-translational modifications .

• Cross-reactivity assessment: Test against related sialyltransferases (ST3GAL1-4, ST3GAL6) to ensure specificity within the ST3GAL family.

• Immunoprecipitation followed by mass spectrometry: For ultimate validation, immunoprecipitate the target protein and confirm identity by mass spectrometry analysis.

Researchers should be particularly cautious when studying ganglioside synthesis pathways as multiple sialyltransferases can have overlapping functions, making specific antibody validation critical for meaningful data interpretation.

What are the critical methodological considerations when using ST3GAL5 antibodies in cancer research?

When designing cancer research experiments with ST3GAL5 antibodies, researchers should implement these methodological considerations:

• Cancer type-specific expression patterns: ST3GAL5 expression varies dramatically between cancer types, displaying opposite patterns and prognostic significance. For example, ST3GAL5 is overexpressed in renal cell carcinoma (associated with poor prognosis) , yet downregulated in bladder cancer and lung squamous cell carcinoma (where higher expression correlates with better outcomes) . Always include appropriate cancer-type controls.

• Spatial heterogeneity assessment: Implement multi-region sampling within tumors, as ST3GAL5 expression can vary between tumor center and margins. Studies have shown differential expression patterns that correlate with immune infiltration status .

• Immune contextualization: Co-stain for immune markers, particularly CD8+ T cells and exhaustion markers like PD-1, as ST3GAL5 expression strongly correlates with immune infiltration patterns. Immunofluorescence co-staining protocols should be optimized to detect the ST3GAL5/immune cell relationship .

• Scoring system standardization: Implement quantitative scoring methods for immunohistochemistry:

  IHC Score	Staining Intensity	Percentage of Positive Cells
  0	No staining	<5%
  1	Weak	5-25%
  2	Moderate	26-50%
  3	Strong	>50%

• Microenvironment context: Consider the impact of stromal and immune cells, as they also express ST3GAL5 and may compensate for lack of tumor cell expression .

• Ganglioside profiling: Complement antibody studies with ganglioside profiling using mass spectrometry or HPLC to correlate ST3GAL5 protein expression with functional enzymatic activity .

How should researchers analyze conflicting data regarding ST3GAL5's role in different cancer types?

The conflicting roles of ST3GAL5 across different cancer types present a methodological challenge. Researchers should approach these contradictions using:

• Multi-modal experimental design: Integrate protein expression (antibody-based methods), mRNA expression analysis, functional enzyme activity assays, and ganglioside profiling to develop a comprehensive view.

• Context-specific analysis: Account for cancer-specific factors that might explain different roles of ST3GAL5:

  • Cell-of-origin differences

  • Pathway dependency variations

  • Tumor microenvironment composition

  • Genetic/epigenetic background

• Mechanistic stratification: Distinguish between direct effects of ST3GAL5 activity versus secondary effects involving:

  • Signal transduction pathway modulation

  • Immune response modification

  • Extracellular matrix/adhesion alterations

• Data integration approach: When analyzing seemingly contradictory data, consider this hierarchical analytical framework:

  Level of Analysis	Methodological Approach	Integration Strategy
  Molecular Function	Enzymatic activity assays combined with ganglioside profiling	Determine if ST3GAL5 protein expression correlates with GM3 synthesis
  Cellular Signaling	Receptor trafficking and pathway activation studies	Assess how ST3GAL5-modified gangliosides affect specific pathways (e.g., TGF-β signaling)
  Tissue Context	Co-expression analysis with immune markers	Evaluate correlation between ST3GAL5 and immune infiltration patterns
  Clinical Outcome	Multivariate survival analysis	Determine if ST3GAL5's prognostic significance is independent or mediated by other factors

• Experimental controls: Include positive control tissues with known ST3GAL5 expression patterns alongside experimental samples to ensure technical consistency.

How can ST3GAL5 antibodies be used to understand ganglioside-mediated immune modulation in cancer?

Recent research has revealed a critical role for ST3GAL5 in modulating anti-tumor immunity through ganglioside synthesis. Advanced methodological approaches include:

What methodologies can elucidate the function of ST3GAL5 genetic variants in disease states?

Recent studies have identified genetic variants in ST3GAL5 with potential implications for disease pathophysiology. Advanced methods to investigate these variants include:

• Promoter haplotype analysis: Researchers have identified four major promoter haplotypes in ST3GAL5 and investigated their functional significance:

  Haplotype ID	Variants	Frequency	Functional Effect
  H1	g.-1930G, g.-1626G, g.-1468C, g.-1051C, g.-141C, g.-140A	0.510	Reference
  H2	g.-1930A, g.-1626G, g.-1468C, g.-1051G, g.-141T, g.-140C	0.260	Decreased promoter activity
  H3	g.-1930A, g.-1626A, g.-1468G, g.-1051C, g.-141C, g.-140C	0.130	Decreased promoter activity
  H4	g.-1930A, g.-1626G, g.-1468C, g.-1051C, g.-141C, g.-140C	0.100	Decreased promoter activity

  Methodology requires luciferase reporter assays to measure promoter activity of different haplotypes .

• Transcription factor binding analysis: Employ electrophoretic mobility shift assays (EMSA) to determine how genetic variants affect transcription factor binding. Research has identified several key transcription factors that regulate ST3GAL5 expression:

  • Activating protein-1 (AP-1)

  • NKX3.1

  • Specificity protein 1 (SP1)

• Nonsynonymous variant functional analysis: For coding variants like H104R (c.311A>G, rs3731824), researchers should:

  • Generate expression constructs with variant sequences

  • Assess protein expression by Western blotting

  • Measure enzymatic activity using in vitro ganglioside synthesis assays

  • Perform structural modeling to predict effects on protein function

• Clinical correlation methods: Integrate genetic findings with clinical phenotyping using:

  • Genotype-phenotype association studies

  • Multivariate analysis to control for confounding factors

  • Longitudinal studies to track disease progression based on genetic variants

How can researchers effectively utilize ST3GAL5 antibodies to investigate TGF-β signaling modulation?

Recent discoveries have revealed that ST3GAL5-derived gangliosides modulate TGF-β signaling, particularly inhibiting TGF-β-induced epithelial-to-mesenchymal transition (EMT). Advanced methodological approaches include:

• Signaling pathway investigation: Combine antibody-based methods with functional assays:

  • Immunoblotting for phosphorylated SMAD2/3 to assess TGF-β pathway activation

  • Dual-luciferase reporter assays with SMAD-responsive elements

  • qRT-PCR analysis of TGF-β target genes

  • RNA-seq to comprehensively profile transcriptional responses

• Receptor dynamics assessment: Advanced protocols to analyze:

  • Ubiquitination status of TGF-β receptor I (TβRI) through immunoprecipitation followed by ubiquitin immunoblotting

  • Lipid raft localization of TGF-β receptors using sucrose gradient fractionation and immunoblotting

  • Receptor half-life studies using cycloheximide chase experiments

• In vivo metastasis models: Implement rigorous methodologies:

  • Zebrafish xenograft models to quantify extravasation capacity

  • Bioluminescent imaging in mouse models to track metastatic spread

  • Cell-line engineering to overexpress or knock down ST3GAL5

• Critical experimental controls: Implement targeted controls:

  • TGF-β pathway inhibitors (e.g., SB505124) to confirm pathway specificity

  • Exogenous ganglioside supplementation to rescue phenotypes

  • Multiple cell lines to ensure generalizability of findings

Recent studies demonstrated that ST3GAL5 knockdown enhanced TGF-β-induced SMAD2 phosphorylation and promoted EMT marker expression, while ST3GAL5 overexpression had opposing effects. ST3GAL5-mediated regulation operated through promoting SMAD7-SMURF2-induced ubiquitination and degradation of TβRI, with GM3 being the primary mediator of this effect .

What are the common technical challenges when using ST3GAL5 antibodies in immunohistochemistry, and how can they be overcome?

Researchers frequently encounter several technical challenges when using ST3GAL5 antibodies for immunohistochemistry. Here are methodological solutions:

• Variable staining intensity: ST3GAL5 expression can vary widely between tissues and disease states.

  • Solution: Implement a tiered antibody dilution series (1:50, 1:100, 1:200, 1:500) for each new tissue type and standardize exposure settings.

  • Optimization: Include positive control tissues (human testis, placenta, or skeletal muscle) on the same slide to normalize staining intensity .

• Background staining: Non-specific binding can complicate interpretation.

  • Solution: Optimize blocking conditions (5% normal serum from the same species as the secondary antibody, plus 1% BSA).

  • Optimization: Include a no-primary antibody control and implement avidin/biotin blocking if using biotinylated secondary antibodies.

• Antigen retrieval challenges: ST3GAL5 epitopes may be masked by fixation.

  • Solution: Compare heat-induced epitope retrieval methods:

    • TE buffer pH 9.0 (preferred for many ST3GAL5 epitopes)

    • Citrate buffer pH 6.0 (alternative approach)

  • Optimization: Test microwave, pressure cooker, and water bath methods for optimal retrieval.

• Post-translational modifications masking: Glycosylation of ST3GAL5 can affect antibody binding.

  • Solution: Consider enzymatic pretreatment with glycosidases before antibody application.

  • Optimization: Test antibodies targeting different epitopes if particular domains are inaccessible.

• Subcellular localization challenges: ST3GAL5 localizes primarily to the Golgi apparatus, requiring high-resolution imaging.

  • Solution: Use confocal microscopy with co-staining for Golgi markers.

  • Optimization: Implement super-resolution techniques for detailed localization studies.

How should researchers address contradictory findings between mRNA and protein expression levels of ST3GAL5?

Discrepancies between ST3GAL5 mRNA and protein levels are common and methodologically challenging. Researchers should implement these approaches:

• Integrated multi-level analysis:

  • Measure mRNA by RT-qPCR and RNA-seq

  • Quantify protein using Western blotting and immunohistochemistry

  • Assess enzymatic activity using functional ganglioside synthesis assays

  • Compare findings to identify discordance patterns

• Post-transcriptional regulation investigation:

  • Analyze microRNA targeting of ST3GAL5 mRNA

  • Assess mRNA stability through actinomycin D chase experiments

  • Investigate RNA-binding proteins that may regulate translation

• Post-translational regulation analysis:

  • Measure protein half-life using cycloheximide chase assays

  • Assess ubiquitination status through immunoprecipitation

  • Investigate proteolytic processing with protease inhibitor experiments

• Technical validation and controls:

  • Use multiple primer pairs targeting different exons for mRNA detection

  • Test multiple antibodies recognizing different epitopes (e.g., N-terminal vs. C-terminal)

  • Include known controls with concordant expression patterns

• Biological interpretation framework: When discrepancies persist after technical validation, consider these biological explanations:

  Observation Pattern	Possible Biological Explanation	Methodological Approach
  High mRNA, Low protein	Enhanced protein degradation or translational inhibition	Proteasome inhibitor experiments, polysome profiling
  Low mRNA, High protein	Increased protein stability or post-transcriptional upregulation	Protein half-life studies, miRNA inhibitor experiments
  Tissue-specific discordance	Alternative splicing or tissue-specific regulatory mechanisms	Isoform-specific detection methods, tissue-specific enhancer analysis

What approaches can resolve contradictory findings on ST3GAL5's role in immune modulation across different cancer types?

The conflicting roles of ST3GAL5 in immune modulation require sophisticated methodological approaches to resolve:

• Tissue-specific immune contextualization:

  • Implement multiplexed immunofluorescence panels specific to each cancer type

  • Quantify immune cell subsets (CD8+ T cells, Tregs, myeloid cells) relative to ST3GAL5 expression

  • Compare immune infiltration patterns between cancer types with opposing ST3GAL5 roles

• Functional immune assays:

  • Co-culture experiments with cancer cells (ST3GAL5 high vs. low) and immune cells

  • T cell activation and cytotoxicity assays in the presence of isolated gangliosides

  • Blocking antibody experiments targeting specific immune receptors (Siglecs) to determine cancer-type specific mechanisms

• Ganglioside-specific analysis:

  • Comprehensive ganglioside profiling across cancer types using LC-MS/MS

  • Comparison of a-, b-, and c-series gangliosides in each cancer type

  • Correlation of specific ganglioside species with immune phenotypes

• Genetic manipulation with precise readouts:

  • CRISPR/Cas9-mediated ST3GAL5 knockout in multiple cancer cell lines

  • Rescue experiments with specific ganglioside species

  • In vivo immune infiltration studies in syngeneic mouse models with ST3GAL5-modified cancer cells

• Framework for resolving contradictions:

  Cancer Type	ST3GAL5 Expression Pattern	Immune Correlation	Methodological Approach
  Renal Cell Carcinoma	Overexpressed vs. normal tissue; poor prognosis	Positive correlation with exhausted CD8+ T cells	IF co-staining for CD8/PD-1, xCell algorithm for immune infiltration analysis
  Colorectal Cancer	Lower expression correlates with better survival	ST3GAL5 KO shows higher Treg frequency	Flow cytometry for immune subset quantification, reporter assays for pathway analysis
  Lung Cancer	Lower in tumor vs. normal tissue; good prognosis	Not fully characterized	TGF-β pathway analysis, zebrafish xenograft models for invasion assessment

Implementing these methodological approaches will help researchers resolve contradictions and develop a unified understanding of ST3GAL5's context-dependent roles across cancer types.

What emerging technologies can advance ST3GAL5 antibody applications in glycobiology research?

Several cutting-edge methodologies are poised to transform ST3GAL5 antibody applications in glycobiology:

• Spatial multi-omics integration:

  • Combining ST3GAL5 antibody-based spatial profiling with glycomics data

  • Implementing multiplexed ion beam imaging (MIBI) or imaging mass cytometry (IMC) for high-parameter spatial analysis

  • Correlating spatial ST3GAL5 expression with glycolipid distribution using MALDI imaging mass spectrometry

• Single-cell glycobiology approaches:

  • Developing methods to analyze ST3GAL5 activity at the single-cell level

  • Implementing flow cytometry with glycan-binding proteins alongside ST3GAL5 antibodies

  • Correlating single-cell transcriptomics with ST3GAL5 protein expression and function

• Advanced proximity labeling techniques:

  • Antibody-directed proximity labeling (APEX or BioID) to identify ST3GAL5 interactors

  • Split-protein complementation assays to study dynamic interactions

  • Enzyme-mediated activation of radical sources (EMARS) to map glycolipid-protein interactions in situ

• CRISPR-based functional screening:

  • Genome-wide CRISPR screens to identify regulators of ST3GAL5 expression

  • CRISPRi/CRISPRa libraries to modulate ST3GAL5 expression and study functional consequences

  • Base editing approaches to introduce specific ST3GAL5 mutations for structure-function studies

• Antibody engineering for enhanced applications:

  • Development of conformation-specific antibodies that recognize active ST3GAL5

  • BiTE (Bispecific T cell Engager) antibodies linking ST3GAL5-expressing cells to immune effectors

  • Intrabodies for tracking ST3GAL5 trafficking in live cells

How can researchers best integrate ST3GAL5 studies with immunotherapy response prediction?

The emerging role of ST3GAL5 in immune regulation presents significant opportunities for immunotherapy response prediction. Methodological approaches should include:

• Predictive biomarker development:

  • Quantitative IHC scoring systems for ST3GAL5 expression

  • Combined analysis of ST3GAL5 with immune checkpoint molecules (PD-1, PD-L1, CTLA-4)

  • Development of predictive algorithms incorporating ST3GAL5 expression with immune cell spatial distributions

• Functional validation approaches:

  • Preclinical models testing immunotherapy efficacy in ST3GAL5-high vs. ST3GAL5-low tumors

  • Ex vivo tumor slice cultures treated with immunotherapy agents

  • Patient-derived organoids with varying ST3GAL5 levels exposed to immunotherapies

• Clinical trial considerations:

  • Retrospective analysis of ST3GAL5 expression in immunotherapy clinical trial samples

  • Prospective trials incorporating ST3GAL5 as a stratification biomarker

  • Longitudinal sampling to track ST3GAL5 expression changes during treatment

• Mechanistic studies of resistance modulation:

  • Investigation of how ST3GAL5-derived gangliosides affect T cell receptor signaling

  • Analysis of ST3GAL5 influence on antigen presentation machinery

  • Study of ganglioside-mediated immune suppression in the tumor microenvironment

• Clinical implementation framework:

  Clinical Scenario	ST3GAL5 Status	Potential Implication	Methodological Approach
  Checkpoint inhibitor therapy	High ST3GAL5, high CD8+PD-1+ cells	Potential resistance mechanism	Multiplex IHC for ST3GAL5, CD8, PD-1; correlation with response
  TGF-β-targeting therapies	Low ST3GAL5 expression	Enhanced TGF-β signaling may predict response	Combining ST3GAL5 IHC with phospho-SMAD2/3 staining
  CAR-T cell therapy	ST3GAL5-high tumors	Potential resistance through T cell exhaustion	Analysis of ganglioside effects on CAR-T function

Research findings indicate that high ST3GAL5 expression correlates with CD8+ T cell exhaustion in renal cell carcinoma, suggesting potential resistance to immunotherapies targeting T cell reinvigoration . Further mechanistic studies are needed to determine whether targeted inhibition of specific gangliosides could enhance immunotherapy efficacy.